BioSpace News Archive

Immorna today announced that the first subject has been dosed in the Company’s First-In-Human (FIH) Phase 1 multi-center study of JCXH-105, a self-replicating RNA (srRNA) vaccine being developed for the prevention of Shingles (Herpes Zoster; HZ).

SK bioscience has announced today the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorization (MA) for SK bioscience’s COVID-19 vaccine SKYCovion™ (brand name in Korea: SKYCovione™) as a primary series for strong immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.

Resonetics, a leading medical contract design and manufacturing organization, announced that Kevin D. Kelly will join the company as President and Chief Executive Officer, effective May 30, 2023.

U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA ® (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer.

Revive Therapeutics Ltd. announced today an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) (NCT04504734) evaluating the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.

Aclarion, Inc. announced their commercial agreement with the prestigious London Clinic, London, UK. The London Clinic is one of the UK’s largest and most renowned independent hospitals.

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today reported financial results for the first quarter of 2023 and provided a business update.

IRLAB Therapeutics AB announced that the company will present at ABGSC’s Life Science Summit on Wednesday, May 31, 2023, in Stockholm, Sweden.

Algiax Pharmaceuticals, provided an update on its ongoing Phase 2a study with lead candidate AP-325 in patients with chronic neuropathic pain.

Allarity Therapeutics, Inc. announced the results of a prospective Phase 2 clinical study of the Company’s proprietary DRP® technology that will be presented in a poster at the 2023 American Society of Clinical Oncology Annual Meeting on June 3, 2023.